<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605796</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-034-II-HCC</org_study_id>
    <nct_id>NCT04605796</nct_id>
  </id_info>
  <brief_title>A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, national multicenter phase II clinical study to&#xD;
      preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with&#xD;
      Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability&#xD;
      and ORR as the primary study objectives and indicators, and plans to enroll about 50-60&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Frequency table will be used to summarize occurrence of each treatment-emergent AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number and incidence of abnormal laboratory examinations by treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The rate of participants that achieve either a complete response (CR) or a partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from the first assessment of CR or PR to the first assessment of PD or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The percentage of cases with remission (PR + CR) and stable lesions (SD) after treatment was assessable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>time from the start of treatment to progression of diease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as time from the start of treatment to progression of disease or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall survival is defined as time from the start of treatment until death due to any reason.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PD-L1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Correlation between PD-L1 expression level in tumor tissue, proportion of strong positive expression of PD-L1</description>
  </other_outcome>
  <other_outcome>
    <measure>TMB</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Correlation betweenTumor mutation burden (TMB) and the efficacy</description>
  </other_outcome>
  <other_outcome>
    <measure>PK</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Pharmacokinetic profile in HCC patients of observed maximum plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>ADA</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Analysis of anti-drug antibody (ADA) during treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group:&#xD;
Toripalimab combined with Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Toripalimab combined with Bevacizumab</intervention_name>
    <description>Experimental group:&#xD;
Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &quot;The patients meeting all the following inclusion criteria can be enrolled in this study:&#xD;
&#xD;
          1. Age of 18-70 years (inclusive), male or female.&#xD;
&#xD;
          2. HCC diagnosed by histopathological examination or Guidelines for Diagnosis and&#xD;
             Treatment of Primary Liver Cancer (2017 Edition).&#xD;
&#xD;
          3. Stage B (middle stage) or C (late stage) HCC determined in accordance with Barcelona&#xD;
             Clinic Liver Cancer staging system (BCLC stage). In case of stage B, the patient must&#xD;
             be unsuitable for surgery and/or local therapy, or have progressive disease after&#xD;
             surgery and/or local therapy, or refuse surgery and/or local therapy (special&#xD;
             instruction and signature required).&#xD;
&#xD;
          4. No previous use of any systemic therapy or HCC.&#xD;
&#xD;
          5. Having ≥ 1 measurable lesion in accordance with RECISTv1.1.&#xD;
&#xD;
          6. Grade A Child-Pugh hepatic function, with no history of hepatic encephalopathy.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-1.&#xD;
&#xD;
          8. Expected survival ≥12 weeks.&#xD;
&#xD;
          9. Adequate hematologic and end-organ function..&#xD;
&#xD;
         10. In case of HBsAg (+) and/or HBcAb (+), HBV DNA is required to be &lt; 500 IU/mL, and it&#xD;
             is required to continue the effective anti-HBV therapy that has been adopted in the&#xD;
             full course, or start to use Entecavir or tenofovir in the full course during the&#xD;
             study. HBV/HCV co-infected patients will be excluded. Patients with a history of HCV&#xD;
             infection but with negative HCV RNA PCR results can be considered uninfected with HCV.&#xD;
&#xD;
         11. Female patients of childbearing potential must receive serum pregnancy test within 7&#xD;
             days before enrollment, have negative result, and agree to use reliable and effective&#xD;
             contraceptive methods during the trial and within 60 days after the last dose of study&#xD;
             drug. The male patients whose partners are women of childbearing potential must agree&#xD;
             to use reliable and effective contraceptive methods during the trial and within 60&#xD;
             days after the last dose of study drug.&#xD;
&#xD;
         12. Being voluntary to participate in the study, sufficiently informed consent and&#xD;
             signature of written informed consent form, with good compliance.&#xD;
&#xD;
        Patients can not be enrolled in the study if any one of the following criteria is&#xD;
        fulfilled:&#xD;
&#xD;
          1. Known cholangiocellular carcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid&#xD;
             hepatocellular carcinoma and hepatic fibrolamellar carcinoma.&#xD;
&#xD;
          2. Malignant tumor except HCC in the past 5 years: however, localized tumor cured in the&#xD;
             study is excluded, including cervical carcinoma in situ, skin basal cell carcinoma and&#xD;
             carcinoma in situ of prostate.&#xD;
&#xD;
          3. Hepatic surgery and/or local therapy or treatment with investigational product for HCC&#xD;
             within 4 weeks prior to enrollment; palliative therapy for bone metastatic lesion&#xD;
             within 2 weeks prior to enrollment. Toxicity reaction induced by previous therapy&#xD;
             (except alopecia) not recovered to ≤ grade 1 (NCI-CTCAE v5.0). Chinese medicine&#xD;
             preparation with anti-liver cancer effect within 2 weeks prior to enrollment.&#xD;
&#xD;
          4. Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious&#xD;
             moderate peritoneal effusion at screening,&#xD;
&#xD;
          5. History of gastrointestinal hemorrhage within 6 months prior to enrollment; the&#xD;
             patients with portal hypertension need to receive gastroscopy to exclude the patients&#xD;
             with &quot;red sign&quot;, if they are considered by investigators to have high risk for&#xD;
             hemorrhage . The patient needs to be excluded if there is a history of &quot;red sign&quot; in&#xD;
             gastroscopy.&#xD;
&#xD;
          6. Having ≥ grade 3 (NCI-CTCAE v5.0) gastrointestinal or non-gastrointestinal fistula at&#xD;
             present.&#xD;
&#xD;
          7. Patients with cancer thrombus in the main trunk of portal vein (Vp4), or cancer&#xD;
             thrombus in inferior vena cava should be excluded. However, the patients with cancer&#xD;
             thrombus in the main trunk of portal vein but unobstructed branch of contralateral&#xD;
             portal vein are allowed to be enrolled.&#xD;
&#xD;
          8. Previous history of serious cardiovascular and cerebrovascular diseases:&#xD;
&#xD;
          9. Having major bleeding and coagulation disorders or other obvious evidence on&#xD;
             hemorrhagic tendency:&#xD;
&#xD;
         10. Medium to large surgical treatment within 4 weeks prior to enrollment, however, not&#xD;
             including diagnostic biopsy.&#xD;
&#xD;
         11. Central nervous system metastasis.&#xD;
&#xD;
         12. Serious, uncured wound, active ulcer or untreated bone fracture.&#xD;
&#xD;
         13. Vaccination of live vaccine within 30 days prior to enrollment.&#xD;
&#xD;
         14. Active autoimmune diseases requiring systemic treatment (i.e., immunomodulatory drug,&#xD;
             corticosteroid or immunosuppressant) in the past 2 years; however, replacement therapy&#xD;
             (e.g., thyroxine, insulin or physiological corticosteroid replacement therapy for&#xD;
             renal or pituitary insufficiency) will not be considered as systemic therapy and is&#xD;
             allowed to be used, and enrollment is allowed.&#xD;
&#xD;
         15. History of clear interstitial lung disease or non-infectious pneumonia, unless induced&#xD;
             by local radiotherapy; history of active tuberculosis.&#xD;
&#xD;
         16. Any serious acute and chronic infection requiring systemic antibacterial, antifungal&#xD;
             or antiviral therapy at screening, not including viral hepatitis.&#xD;
&#xD;
         17. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         18. Previously receiving allogeneic stem cell or solid organ transplantation.&#xD;
&#xD;
        20. Known history of serious allergy to any monoclonal antibody, anti-angiogenesis targeted&#xD;
        drug.&#xD;
&#xD;
        &quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>bifeng Liu</last_name>
    <phone>86-18967116090</phone>
    <email>bifeng_liu@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chunyi hao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

